**Name of Journal:** *World Journal of Hypertension*

**Manuscript NO:** 81848

**Manuscript Type:** MINIREVIEWS

**Role of major adipokines in hypertension: A literature review**

Rafaqat S *et al*. Role of major adipokines in hypertension

Saira Rafaqat, Sobia Nasreen, Sana Rafaqat

**Saira Rafaqat, Sobia Nasreen**, Department of Zoology, Lahore College for Women University, Lahore 54000, Pakistan

**Sana Rafaqat,** Department of Biotechnology, Lahore College for Women University, Lahore 54000, Pakistan

**Author contributions:**  Rafaqat S carried out the study design and data collection; Rafaqat S and Rafaqat S wrote the manuscript; Nasreen S gave the editing services of the manuscript; all authors read and approved the final manuscript.

**Corresponding author: Saira Rafaqat, PhD, Lecturer,** Department of Zoology, Lahore College for Women University, Near Wapda Flats Jail Road, Jubilee Town, Lahore 54000, Pakistan. saera.rafaqat@gmail.com

**Received:** November 26, 2022

**Revised:** February 11, 2023

**Accepted:** March 6, 2023

**Published online:** March 24, 2023

**Abstract**

The incidence and prevalence of hypertension are increasing as a consequence of the obesity epidemic. Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure. The pathophysiologic states of hypertension, including obesity, are regulated by the production of adipocyte-derived factors. Increased body mass index was closely linked to elevated blood pressure. Mostly the hypertensive subjects were obese as well as overweight. There are numerous adipokines, however, this review article only focuses on the major adipokines including chemerin, visfatin, retinol-binding protein 4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, omentin-1, lipocalin-2, [vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1), progranulin**,** complement c1q tumor necrosis factor-related protein, and nesfatin-1 role in the pathogenesis of hypertension. This review article concludes the significant association of major adipokines in the pathogenesis of hypertensives. New research should be focused on other newly reported adipokine roles in hypertensive subjects and the management of these adipokines in hypertensive subjects. The discovery of this information could result in the creation of antihypertensive medications, particularly those that focus on obesity-related hypertension.

**Key Words:** Chemerin, Visfatin, Retinol-Binding Protein 4, Plasminogen Activator Inhibitor-1, Monocyte Chemotactic Protein-1, Omentin-1, Lipocalin-2, [Vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1), Progranulin**,** Nesfatin-1

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Rafaqat S, Nasreen S, Rafaqat S. Role of major adipokines in hypertension: A literature review. *World J Hypertens* 2023; 11(1): 1-11

**URL**: https://www.wjgnet.com/2220-3168/full/v11/i1/1.htm

**DOI**: https://dx.doi.org/10.5494/wjh.v11.i1.1

**Core Tip:** Many studies have reported the role of adipokines in hypertension. Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure. The risk of hypertension and cardiovascular diseases increase due to obesity mainly central obesity. However, this review article only focuses on the major adipokines such as chemerin, visfatin, retinol-binding protein 4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, omentin-1, lipocalin-2, vaspin, progranulin, complement C1q tumor necrosis factor-related proteins, and nesfatin-1 role in hypertension which were not reported collectively. Further studies require to find the exact mechanism of action of these adipokines in hypertensive subjects and therapeutic approaches are required to control the increasing prevalence of hypertension with obesity, which ultimately reduces the incidence of obesity-associated hypertension and cardiovascular diseases.

**INTRODUCTION**

The risk of hypertension and cardiovascular diseases increase due to obesity mainly central obesity. At least two-thirds of the prevalence of hypertension may be directly attributed to obesity, according to many population-based studies that revealed the estimated risk of hypertension[1]. Many studies have reported the role of adipokines in hypertension. Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure. The pathophysiologic states of hypertension including obesity are regulated by the production of adipocyte-derived factors. In the same way, Yiannikouris *et al*[2], 2010, explained the adipokines in blood pressure control. There were a few adipokines such as leptin, adiponectin, perivascular relaxation factor, renin-angiotensin system, and resistin. Also, Vlasova *et al*[3], 2010, studied the adipokines in obesity-associated hypertension such as interleukin-6, TNF-α, resistin, leptin, adiponectin, and apelin. Likewise, Kim *et al*[4], 2020, assessed a few newly discovered adipokines in obesity and cardiometabolic disorders including lipocalin-2, SFRP5, omentin-1, asprosin, FAM19A5, neuregulin 4.

However, this review article only focuses on the major adipokines such as chemerin, visfatin, retinol-binding protein 4 (RBP4), plasminogen activator inhibitor-1 (PAI-1), monocyte chemotactic protein-1 (MCP-1), omentin-1, lipocalin-2, [vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1), progranulin (PGRN)**,** complement C1q tumor necrosis factor-related proteins (CTRPs), and nesfatin-1 role in hypertension which were not reported collectively as explained in Figure 1.

There are many keywords which have been used including chemerin, visfatin, RBP4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, omentin-1, lipocalin-2, [vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1), progranulin, andnesfatin-1. Google Scholar, PubMed, Science Direct and other different databases were used to review the literature. May 15, 2022 was the last date for the search. The language of clinical studies was restricted to English.

**ROLE OF MAJOR ADIPOKINES IN HYPERTENSION**

There are numerous adipokines, but this review article only focuses on chemerin, visfatin, RBP4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, omentin-1, lipocalin-2, [vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1), progranulin**,** complement C1q tumor necrosis factor-related protein, and nesfatin-1 role in hypertension as explains in Table 1.

**CHEMERIN**

Chemerin is a very recent adipokine. Chemerin was once categorized as a chemokine because of its immune system origins. Chemerin activates tissue macrophages as well as natural killer cells, plasmacytoid dendritic cells, and dendritic cells. According to several studies, circulating chemerin was substantially correlated with positive blood pressure, body mass index, and visceral fat. It was recognized as an adipokine in 2007, and the receptor via which it was discovered to function was known as chemerin chemokine-like receptor 1 (CMKLR1) or ChemR23, which is now known as Chemerin 1. In vascular smooth muscle cells, chemerin is a mitogen when infused in the mouse that elevates the blood pressure. The long-term remodeling of blood vessels in hypertension was the proliferative effect which might be influenced due to chemerin[5].

In the obesity and metabolic syndrome state, chemerin was a new adipokine with elevated concentration. Gu *et al*[6], 2014, study stated the role of chemerin in hypertension which explained that a high chemerin level was an independent predictor of the presence of hypertension when metabolic variables were adjusted in the logistic regression analysis. In hypertensive subjects, components of the metabolic syndrome as well as markers of inflammation were strongly related to chemerin and independently linked to hypertension after adjustment for age, gender, and metabolic risk factors. Additionally, an independent relationship was found between chemerin levels with an index of arterial function as well as early atherosclerosis in essential hypertension[7]. Also, Wójcik *et al*[8], 2020, concluded that increased systolic blood pressure could be linked to elevated chemerin levels in obese children.

Chemerin elicits a variety of functions *via* CMKLR1. Yamamoto *et al*[9], 2021, reported increased protein expression of chemokine-like receptor 1 in the paraventricular nucleus for the first time, which was at least partly responsible for systemic hypertension in spontaneously hypertensive rats. Moreover, Ferland *et al*[10], 2019, study resulted that Chemerin, which was generated from adipose tissue rather than the liver, was a key factor in the relationship between hypertension and excessive fat intake. This information might influence the development of antihypertensive medications, particularly those that target obesity-related hypertension.

**VISFATIN**

In hypertensive patients, the mean visfatin level was significantly higher. It was also found significantly higher in the prehypertensive group compared to participants with normal blood pressure. Visfatin levels, systolic blood pressure, and diastolic blood pressure were found significantly positive correlation[11]. Likewise, Wang *et al*[12], 2010, study demonstrated that Lyon hypertensive rats had elevated levels of serum visfatin which were linked with lipid metabolic abnormalities. Similarly, Liakos *et al*[13], 2015, the study reported significantly higher levels of visfatin in high normal BP subjects. It has been examined as a marker for detecting phases of essential hypertension and may induce vascular inflammation as well as the destabilization of atherosclerotic plaque. In the same way, Yu *et al*[14], 2019, concluded a higher level of plasma visfatin concentration in cerebrovascular accident and hypertension patients compared to healthy subjects.

Additionally, Kocelak *et al*[15], 2014, found a positive correlation between plasma visfatin/nicotinamide phosphoribosyl transferase (NAMPT) concentrations with inflammation and insulin resistance and are decreased in the oldest. Plasma levels of visfatin/NAMPT were not linked to the presence of hypertension in elderly subjects. Moreover, Hsu *et al*[16], 2016, reported the association between a subsequent renal function with increased circulating visfatin in nondiabetic hypertensive patients.

Also, Parimelazhagan *et al*[17], 2021, stated a positive correlation between visfatin and high-density lipoproteins as well as diastolic blood pressure. Visfatin levels were revealed to be elevated and associated with pro-inflammatory cytokines in hypertensive individuals with hypertriglyceridemia. The most frequent comorbidity in cancer patients has been identified as hypertension, and visfatin may represent a unique potential therapeutic target for this condition in both cancer patients and survivors. In the contribution to the pathogenesis of hypertension in patients with visceral obesity, increased plasma visfatin concentration could play a significant role. In patients with visceral obesity, activation of the Renin-Angiotensin-Aldosterone System by dietary salt restriction and upright positioning did not affect plasma visfatin levels[18].

***Retinol-binding protein 4***

RBP4 is mainly secreted by adipocytes with 21-KDa adipokines. It has a role in the induction of insulin resistance, also closely linked to cardiovascular diseases and other risk factors including coronary heart disease, obesity, hypertension, hyperlipidemia, and heart failure[19]. Increased prevalence of hypertension, as well as myocardial infarction, were correlated with elevated levels of serum RBP4 which also contribute to insulin resistance. Blood pressure increases due to elevated serum levels of RBP4 and lack of RBP4 reduce it, with commensurate changes in aortic eNOS (Ser1177) phosphorylation. To reduce blood pressure, RBP4 levels can be lowered through enhanced eNOS- mediated vasodilatation and could be a novel therapeutic approach for hypertension[20].

Moreover, Li *et al*[21], 2019, explained that hypertension is a leading cause of death as well as cardiovascular disease. The increased range of cardiovascular diseases is due to RBP4 which is an inflammatory factor. In individuals with essential hypertension, blood pressure levels were strongly connected with RBP4, which may be regulating left ventricular diastolic function. Cardiovascular disease, as well as blood pressure, were correlated with circulating RBP4[22-25], potentially also secondary to reduced renal clearance due to hypertensive nephropathy[26].

Furthermore, Deng *et al*[27], 2014, elucidated that RBP4 is a novel adipokine which modulates the action of insulin in numerous diseases and insulin resistance correlated with cardiovascular disease. After adjusting for body mass index, waist circumference, and waist-hip ratio, a modestly linear relationship was observed between RBP4 levels and systolic blood pressure, diastolic blood pressure and HOMA-β. In conclusion, the authors explain the elevated levels of RBP4 in naïve hypertension patients; no variations were seen in obese or non-obese hypertensive people. For the first time, researchers suggested that RBP4 was considerably elevated in newly diagnosed hypertensive Chinese patients but did not play a role in the development of insulin resistance.

Solini *et al*[22], 2009, showed that retinol-binding protein-4 levels were higher in nave hypertensive women and linked with the degree of carotid intima-media thickness, suggesting that this adipocytokine may be involved in the regulation of the atherosclerotic process exerted by adipose tissue as an endocrine organ. Likewise, Zhang *et al*[28], 2017, demonstrated that the RBP4 level was independently linked with systolic blood pressure and diastolic blood pressure. Serum RBP4 level was significantly higher and closely linked with blood pressure in the prehypertensive Chinese population. Moreover, Stuck *et al*[29], 2010, concluded that in addition to the current conventional treatment for hypertension, which focuses on inhibiting the angiotensin system, reducing serum RBP4 may be a unique therapeutic strategy for the condition.

**PLASMINOGEN ACTIVATOR INHIBITOR-1**

Over 35% increased risk of developing hypertension was linked to a higher level of plasma PAI-1 in a high-risk population. Peng *et al*[30], 2017, resulted that plasma plasminogen activator inhibitor-1 could contribute to the development of hypertension through pathways beyond traditional risk factors. PAI-1 levels were correlated with plasma renin activity, aldosterone, and insulin resistance in hypertensive subjects. Therefore, the authors suggested that aldosterone could be a vital factor contributing to the variability of plasminogen activator inhibitor-1 levels in hypertensive subjects[31]. Moreover, Kaikita *et al*[32], 2001, showed that in the presence of long-term NOS inhibition, PAI-1 impairment was sufficient to prevent the structural vascular alterations associated with hypertension. For the prevention of arteriosclerotic cardiovascular disease, direct inhibition of vascular plasminogen activator inhibitor-1 activity could provide a new therapeutic strategy.

**MONOCYTE CHEMOTACTIC PROTEIN-1**

The pathogenesis of metabolic syndrome and various metabolic parameters including essential hypertension, obesity, and diabetes have involved the contribution of MCP-1. The quantitative evaluation of MCP-1 was a diagnostic as well as a prognostic marker of atherosclerotic disease[33]. Both resistant and hypertensive subjects had similar levels of MCP-1 and decreased in hypertensive subjects with existing left ventricular hypertrophy. The authors suggested possible downregulation in MCP-1 levels in hypertensive patients with left ventricular hypertrophy, regardless of hypertension strata[34]. In the same line, Wang *et al*[35], 2015, reported for the first time which indicated that the deletion of transient receptor potential vanilloid type 1 (TRPV1) aggravated the renal injury in salt-sensitive hypertension *via* enhancing MCP-1/C-C Motif Chemokine Receptor 2 (CCR2) signaling-dependent inflammatory responses.

**OMENTIN-1**

Omentin-1 is released from visceral adipose tissue, visceral fat, stromal vascular cells, and endothelial cells. It is a glycoprotein of the adiponectin family which has an anti-inflammatory effect. Waist circumference, body mass index, and insulin resistance were negatively correlated with circulating omentin-1. In addition, serum omentin-1 was employed as a biomarker for conditions such as metabolic syndrome, diabetes mellitus, coronary artery disease, cancer, atherosclerosis, and inflammatory illnesses. Both stage 1 and 2 HT subgroups had lowered levels of omentin-1 as compared with normotensive control (72.19 ± 54.33 ng/mL for the stage 1 HT subgroup; 62.45 ± 47.01 ng/mL for the stage 2 HT subgroup; and, 147.84 ± 58.55 ng/mL for healthy normotensive controls; overall *P* < 0.001). In addition, the authors demonstrated that serum omentin-1 levels decreased in patients with hypertension as compared with normotensive controls which could be attributed to a combined outcome of endothelial dysfunction, inflammation as well as renal injury in the setting of hypertension[36].

Tetrahydroxystilbene glycoside (TSG) exhibits a preventive as well as hypotensive impact on endothelial dysfunction and obesity-related hypertension through increased level of omentin-1. Omentin-1 plays a vital role in the process of endothelial dysfunction and obesity-related hypertension. In conclusion, the authors explained that the down-regulation of omentin-1 induces endothelial dysfunction and hypertension in obesity. Tetrahydroxystilbene [glycoside](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/glycoside) treatment (at least partially) increases omentin-1 *via* promoting the binding of peroxisome proliferator-activated receptor-γ (PPAR-γ) and intelectin-1 (*Itln-1)* promoter in adipose tissues, subsequently exerts protective effects on endothelial function *via* activating Akt/eNOS/NO signaling and attenuating oxidative/nitrative stress. According to the findings, TSG may be developed as a potent anti-hypertension drug that prevents endothelial dysfunction and obesity-related cardiovascular disorders[37]. On the other hand, Cetin *et al*[38], 2022, suggested that Circulating omentin-1 levels were negatively correlated with the existence of metabolic syndrome and might serve as an accurate diagnostic to anticipate the onset of metabolic syndrome in hypertensive individuals.

**LIPOCALIN-2**

Lipocalin- is a proinflammatory adipokine which is upregulated in obese humans as well as animals. The harmful involvement of lipocalin-2 in people with hypertension was proposed by the authors. Mice lacking lipocalin-2 were protected against the cardiovascular impairment brought on by diet-induced obesity. Mice fed a high-fat diet have aberrant vasodilator responses after receiving lipocalin-2. The removal of lipocalin-2 was facilitated by Polyamination, whereas the buildup of deamidated lipocalin-2 in arteries results in vascular inflammation, endothelial dysfunction, and hypertension[39].

Obesity and inflammation are risk factors for hypertension and lipocalin-2 has recently been recognized as a biomarker of these two diseases. Haplotype GGTCC was linked to the progress of higher blood pressure at follow-up after adjusting for baseline age, sex, systolic blood pressure, and follow-up duration. Among subjects not taking antihypertensive medication, carriers of the haplotype GGTCC had higher systolic blood pressure compared to noncarriers. For the first time, the researchers presented that blood pressure may be impacted by genetic variations in LCN2. More research is needed to better understand how lipocalin-2 controls blood pressure[40]. Whereas, Chen *et al*[41], 2020, examined the contributing role of LCN2 in liver fibrosis as well as portal hypertension in alcoholic hepatitis and might represent a new therapeutic target.

[**VASPIN**](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1)

Vaspin is a relatively novel adipocytokine and visceral adipose tissue-derived serine protease inhibitor which has a protective effect against metabolic diseases such as type II diabetes as well as obesity. Vaspin exerts a role in anti-migratory as well as anti-inflammatory through antioxidative effects in vascular smooth muscle cells. For the pathogenesis of hypertension, inflammatory responses, as well as migration of smooth muscle in the peripheral vascular wall, are key mechanisms. The prevention of elevated SBP was significantly prevented by long-term vaspin treatment at 8 wk of age. No reactivity of isolated mesenteric artery did not affect vaspin in spontaneously hypertensive rats (SHR). Oppositely, Vaspin dramatically reduced mesenteric artery wall hypertrophy in SHR, as well as the expression of tumor necrosis factor-alpha and the generation of reactive oxygen species in isolated SHR mesenteric arteries. In conclusion, the authors showed for the first time that vaspin reduces the rise in SBP in SHR by preventing peripheral vascular hypertrophy, probably through antioxidative and anti-inflammatory mechanisms[42].

In contrast, Fathey *et al*[43], 2022, reported vaspin levels and high blood pressure were inversely correlated. The newly diagnosed uncomplicated hypertensive patients' group had serum vaspin levels that were lower than those of the control group, and those with macrovascular and/or microvascular complications had serum vaspin levels that were significantly lower than those of both the uncomplicated hypertensive and control groups. The early diagnosis of macrovascular and/or microvascular hypertension problems may be possible using plasma vaspin as a independent predictive biomarker.

**PROGRANULIN**

Progranulin, one of the adipokines produced by adipose tissue, is a multifunctional regulatory protein having neuroprotective, growth-promoting, and anti-inflammatory properties. Visceral adipose tissue expresses it, and obesity raises the level of circulating progranulin, which plays a role in the pathophysiology of insulin resistance linked to obesity[44].

Kaur *et al*[45], 2020, examined that elevated PGRN levels in response to elevated tumor necrosis factor-α (TNF-α) levels depict the counter-regulation by progranulin to neutralize tumor necrosis factor-α. Findings of reduced PGRN/TNF ratio, and it was an independent predictor of SBP, ascertain the key role of imbalance in the pro-and anti-inflammatory environment in hypertension. As a result, the vicious network idea linking immunity, obesity, inflammation, and blood pressure was strengthened. Moreover, long-term studies must be conducted to examine this SBP and progranulin cross-link. Finding a balance between the pro- and anti-inflammatory states in future research would allow for the exploration of novel target areas for the treatment of hypertension rather than just focusing on the effects of the pro-inflammatory environment.

**C1Q TUMOR NECROSIS FACTOR-RELATED PROTEINS**

The adipokine superfamily's C1q tumor necrosis CTRPs, which are homologs of adiponectin and have a variety of roles as well as a tight association with metabolic illnesses such improper lipid metabolism, high blood sugar, and diabetes. Moreover, CTRPs have highly participated in the regulation of various pathological processes as well as physiological processes such as protein kinase pathways, inflammation, cell proliferation, glycolipid metabolism, and cell apoptosis[46]. Additionally, Han *et al*[47], 2018, reported that CTRP1 involvement in the regulation of blood pressure homeostasis by preventing dehydration-induced hypotension for the first time.

In this regard, Su *et al*[48], 2019, concluded a potential biomarker for the prognosis of patients with essential hypertension may be CTRP1 levels, which were found to be elevated and associated with subclinical target organ damage (STOD) in essential hypertension, including damage to the heart and kidney. Recently discovered adipokine CTRP1 was found to increase aldosterone synthesis in the adrenocortical carcinoma cell line H295R, suggesting that it may be a pathophysiologic connection between hyperaldosteronism and hypertension in overweight and obese individuals. Also, Seccia *et al*[49] reported that CTRP-1 expression extends beyond adipocytes and occurs in both healthy and abnormal adrenocortical tissues supporting the idea that CTRP-1 modulates aldosterone synthesis in both the healthy zona glomerulosa and in adenomas that produce aldosterone, albeit *via* unidentified receptors and signalling mechanisms. The fact that CTRP-1 was expressed in myelolipomas together with adenomas that produce aldosterone raises the possibility that CTRP-1 may cause an excess of aldosterone and the growth of ZG cells.

**NESFATIN-1**

In addition to the central mechanism, the brain and peripheral tissues also play a role in the control of blood pressure in vivo via altering vascular contractility. Patients with type 2 diabetes or metabolic syndrome may experience hypertension due to nesfatin-1 or its precursor protein, nesfatin/NUCB2. Nesfatin-1, a novel essential molecule, may have a role in hypertension and be utilized to treat obesity and type 2 diabetes[50].

In the same way, Zhao *et al*[51], 2015, found that nesfatin-1 levels in fasting plasma were shown to be significantly higher in hypertension patients than in control groups, particularly in patients who were overweight or obese. Nesfatin-1 may be crucial in the development of obesity-related hypertension and may also raise the chance of developing this condition. In the same context, Güneş *et al*[52], 2020, concluded that Nesfatin-1 concentrations were elevated and an independent predictor of hypertension in obese patients. The hypertension group had greater body mass index, weight, and serum Nesfatin-1 concentrations. Also, Lu *et al*[53], 2018, investigated nesfatin-1 as a key modulator in vascular remodeling and hypertension by facilitating vascular smooth muscle cell phenotypic switching and proliferation.

**CONCLUSION**

This review concludes with the association between major adipokines with elevated blood pressure. Likewise, numerous studies have reported the elevated concentration of chemerin, visfatin, RBP4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, lipocalin-2, progranulin**,** complement c1q tumor necrosis factor-related protein, and nesfatin-1 in the hypertension patients. In contrast, omentin-1 and [vaspin](https://en.wikipedia.org/w/index.php?title=Vaspin&action=edit&redlink=1) had lowered concentrations in hypertensive subjects. There are other newly reported adipokines including follistatin-like 1, secreted protein acidic and rich in cysteine, secreted frizzled-related protein 5, a family with sequence similarity to 19 members A5, wingless-type inducible signaling pathway protein-1 need to focus on the association with hypertension. Further studies require to find the exact mechanism of action of these adipokines in hypertensive subjects and therapeutic approaches are required to control the increasing prevalence of hypertension with obesity, which ultimately reduces the incidence of obesity-associated hypertension and cardiovascular diseases.

**ACKNOWLEDGEMENTS**

The corresponding author thanks her mother, Mrs Tahira Rafaqat and father, Mr Rafaqat Masih.

**REFERENCES**

1 **Narkiewicz K**. Obesity and hypertension--the issue is more complex than we thought. *Nephrol Dial Transplant* 2006; **21**: 264-267 [PMID: 16311261 DOI: 10.1093/ndt/gfi290]

2 **Yiannikouris F**, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. *Curr Opin Nephrol Hypertens* 2010; **19**: 195-200 [PMID: 20051852 DOI: 10.1097/MNH.0b013e3283366cd0]

3 **Vlasova M**, Purhonen AK, Jarvelin MR, Rodilla E, Pascual J, Herzig KH. Role of adipokines in obesity-associated hypertension. *Acta Physiol (Oxf)* 2010; **200**: 107-127 [PMID: 20653609 DOI: 10.1111/j.1748-1716.2010.02171.x]

4 **Kim JA**, Choi KM. Newly Discovered Adipokines: Pathophysiological Link Between Obesity and Cardiometabolic Disorders. *Front Physiol* 2020; **11**: 568800 [PMID: 32982804 DOI: 10.3389/fphys.2020.568800]

5 **Ferland DJ**, Mullick AE, Watts SW. Chemerin as a Driver of Hypertension: A Consideration. *Am J Hypertens* 2020; **33**: 975-986 [PMID: 32453820 DOI: 10.1093/ajh/hpaa084]

6 **Gu P**, Jiang W, Lu B, Shi Z. Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. *Clin Exp Hypertens* 2014; **36**: 326-332 [PMID: 24047472 DOI: 10.3109/10641963.2013.827697]

7 **Gu P**, Cheng M, Hui X, Lu B, Jiang W, Shi Z. Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients. *J Hypertens* 2015; **33**: 1624-1632 [PMID: 26136068 DOI: 10.1097/HJH.0000000000000588]

8 **Wójcik M**, Kozioł-Kozakowska A, Januś D, Furtak A, Małek A, Sztefko K, Starzyk JB. Circulating chemerin level may be associated with early vascular pathology in obese children without overt arterial hypertension - preliminary results. *J Pediatr Endocrinol Metab* 2020; **33**: 729-734 [PMID: 32469331 DOI: 10.1515/jpem-2019-0460]

9 **Yamamoto A**, Otani K, Okada M, Yamawaki H. Chemokine-like Receptor 1 in Brain of Spontaneously Hypertensive Rats Mediates Systemic Hypertension. *Int J Mol Sci* 2021; **22** [PMID: 34769243 DOI: 10.3390/ijms222111812]

10 **Ferland DJ**, Flood ED, Garver H, Yeh ST, Riney S, Mullick AE, Fink GD, Watts SW. Different blood pressure responses in hypertensive rats following chemerin mRNA inhibition in dietary high fat compared to dietary high-salt conditions. *Physiol Genomics* 2019; **51**: 553-561 [PMID: 31588871 DOI: 10.1152/physiolgenomics.00050.2019]

11 **Gunes F**, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. *Intern Med* 2012; **51**: 553-557 [PMID: 22449661 DOI: 10.2169/internalmedicine.51.6609]

12 **Wang P**, Bai C, Xu QY, Xu TY, Su DF, Sassard J, Miao CY. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. *Clin Exp Pharmacol Physiol* 2010; **37**: 894-899 [PMID: 20456420 DOI: 10.1111/j.1440-1681.2010.05402.x]

13 **Liakos CI**, Sanidas EA, Perrea DN, Grassos CA, Chantziara V, Viniou NA, Barbetseas JD, Papadopoulos DP. Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure. *Am J Hypertens* 2016; **29**: 549-552 [PMID: 26276791 DOI: 10.1093/ajh/hpv136]

14 **Yu PL**, Wang C, Li W, Zhang FX. Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis. *Horm Metab Res* 2019; **51**: 220-229 [PMID: 31022738 DOI: 10.1055/a-0867-1333]

15 **Kocelak P**, Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Więcek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy. *J Am Soc Hypertens* 2015; **9**: 1-8 [PMID: 25537462 DOI: 10.1016/j.jash.2014.11.002]

16 **Hsu CY**, Huang PH, Chen TH, Chiang CH, Leu HB, Huang CC, Chen JW, Lin SJ. Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients. *Am J Hypertens* 2016; **29**: 528-536 [PMID: 26298010 DOI: 10.1093/ajh/hpv132]

17 **Parimelazhagan R**, Umapathy D, Sivakamasundari IR, Sethupathy S, Ali D, Kunka Mohanram R, Namasivayan N. Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients. *Biomed Res Int* 2021; **2021**: 8568926 [PMID: 33816632 DOI: 10.1155/2021/8568926]

18 **Rotkegel S**, Chudek J, Spiechowicz-Zaton U, Ficek R, Adamczak M, Wiecek A. The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity. *Kidney Blood Press Res* 2013; **37**: 124-131 [PMID: 23615125 DOI: 10.1159/000350066]

19 **Ji Y**, Song J, Su T, Gu X. Adipokine Retinol Binding Protein 4 and Cardiovascular Diseases. *Front Physiol* 2022; **13**: 856298 [PMID: 35309061 DOI: 10.3389/fphys.2022.856298]

20 **Kraus BJ**, Sartoretto JL, Polak P, Hosooka T, Shiroto T, Eskurza I, Lee SA, Jiang H, Michel T, Kahn BB. Novel role for retinol-binding protein 4 in the regulation of blood pressure. *FASEB J* 2015; **29**: 3133-3140 [PMID: 25911613 DOI: 10.1096/fj.14-266064]

21 **Li X**, Zhu S, Song G, Zhang K, Gao W, Huang J, Lu X. Retinol-binding protein 4 is closely correlated to blood pressure level and E/A in untreated essential hypertension patients. *Ann Palliat Med* 2019; **8**: 645-650 [PMID: 31865725 DOI: 10.21037/apm.2019.11.07]

22 **Solini A**, Santini E, Madec S, Rossi C, Muscelli E. Retinol-binding protein-4 in women with untreated essential hypertension. *Am J Hypertens* 2009; **22**: 1001-1006 [PMID: 19556974 DOI: 10.1038/ajh.2009.116]

23 **Meisinger C**, Rückert IM, Rathmann W, Döring A, Thorand B, Huth C, Kowall B, Koenig W. Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the Cooperative Health Research in the Region of Augsburg (KORA) F4 Study. *Diabetes Care* 2011; **34**: 1648-1650 [PMID: 21617096 DOI: 10.2337/dc11-0118]

24 **Sun Q**, Kiernan UA, Shi L, Phillips DA, Kahn BB, Hu FB, Manson JE, Albert CM, Rexrode KM. Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: a prospective analysis among women in the nurses' health study. *Circulation* 2013; **127**: 1938-1947 [PMID: 23584360 DOI: 10.1161/CIRCULATIONAHA.113.002073]

25 **Li ZZ**, Lu XZ, Liu JB, Chen L. Serum retinol-binding protein 4 Levels in patients with diabetic retinopathy. *J Int Med Res* 2010; **38**: 95-99 [PMID: 20233518 DOI: 10.1177/147323001003800111]

26 **Majerczyk M**, Choręza P, Bożentowicz-Wikarek M, Brzozowska A, Arabzada H, Owczarek A, Mossakowska M, Grodzicki T, Zdrojewski T, Więcek A, Olszanecka-Glinianowicz M, Chudek J. Increased plasma RBP4 concentration in older hypertensives is related to the decreased kidney function and the number of antihypertensive drugs-results from the PolSenior substudy. *J Am Soc Hypertens* 2017; **11**: 71-80 [PMID: 28038989 DOI: 10.1016/j.jash.2016.11.009]

27 **Deng W**, Zhang Y, Zheng Y, Jiang Y, Wu Q, Liang Z, Yang G, Chen B. Serum retinol-binding protein 4 Levels are elevated but do not contribute to insulin resistance in newly diagnosed Chinese hypertensive patients. *Diabetol Metab Syndr* 2014; **6**: 72 [PMID: 24932224 DOI: 10.1186/1758-5996-6-72]

28 **Zhang JX**, Zhu GP, Zhang BL, Cheng YY. Elevated serum retinol-binding protein 4 Levels are correlated with blood pressure in prehypertensive Chinese. *J Hum Hypertens* 2017; **31**: 611-615 [PMID: 28639612 DOI: 10.1038/jhh.2017.44]

29 **Stuck BJ,** Kahn BB. Role for Retinol-Binding Protein 4 in Blood Pressure Regulation. InDIABETES 2010 Jun 1 (Vol. 59, pp. A241-A241). 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC. Available from: https://professional.diabetes.org/abstract/role-retinol-binding-protein-4-blood-pressure-regulation

30 **Peng H**, Yeh F, de Simone G, Best LG, Lee ET, Howard BV, Zhao J. Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study. *J Hypertens* 2017; **35**: 1787-1793 [PMID: 28379891 DOI: 10.1097/HJH.0000000000001375]

31 **Srikumar N**, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. *Am J Hypertens* 2002; **15**: 683-690 [PMID: 12160190 DOI: 10.1016/S0895-7061(02)02952-7]

32 **Kaikita K**, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. *Circulation* 2001; **104**: 839-844 [PMID: 11502712 DOI: 10.1161/hc3301.092803]

33 **Komiyama M**, Takanabe R, Ono K, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Morimoto T, Shimatsu A, Takahashi Y, Hasegawa K. Association between monocyte chemoattractant protein-1 and blood pressure in smokers. *J Int Med Res* 2018; **46**: 965-974 [PMID: 29098933 DOI: 10.1177/0300060517723415]

34 **Ritter AMV**, Faria APC, Sabbatini A, Corrêa NB, Brunelli V, Modolo R, Moreno H. MCP-1 Levels are Associated with Cardiac Remodeling but not with Resistant Hypertension. *Arq Bras Cardiol* 2017; **108**: 331-338 [PMID: 28380135 DOI: 10.5935/abc.20170033]

35 **Wang Y**, Zhu M, Xu H, Cui L, Liu W, Wang X, Shen S, Wang DH. Role of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension. *Exp Biol Med (Maywood)* 2015; **240**: 1223-1234 [PMID: 25585624 DOI: 10.1177/1535370214565970]

36 **Çelik M**, Nar R, Nar G, Sökmen E, Günver G. Serum omentin-1 Levels in hypertensive patients. *J Hum Hypertens* 2021; **35**: 290-295 [PMID: 32978495 DOI: 10.1038/s41371-020-00420-4]

37 **Dong Q**, Xing W, Li K, Zhou X, Wang S, Zhang H. Tetrahydroxystilbene glycoside improves endothelial dysfunction and hypertension in obese rats: The role of omentin-1. *Biochem Pharmacol* 2021; **186**: 114489 [PMID: 33647262 DOI: 10.1016/j.bcp.2021.114489]

38 **Cetin Sanlialp S**, Nar G, Nar R. Relationship between circulating serum omentin-1 Levels and nascent metabolic syndrome in patients with hypertension. *J Investig Med* 2022; **70**: 780-785 [PMID: 34857627 DOI: 10.1136/jim-2021-002071]

39 **Song E**, Fan P, Huang B, Deng HB, Cheung BM, Félétou M, Vilaine JP, Villeneuve N, Xu A, Vanhoutte PM, Wang Y. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. *J Am Heart Assoc* 2014; **3**: e000837 [PMID: 24721803 DOI: 10.1161/JAHA.114.000837]

40 **Ong KL**, Tso AW, Cherny SS, Sham PC, Lam TH, Lam KS, Cheung BM; Investigators of the Hong Kong Cardiovascular Risk Factor Prevalence Study. Role of genetic variants in the gene encoding lipocalin-2 in the development of elevated blood pressure. *Clin Exp Hypertens* 2011; **33**: 484-491 [PMID: 21978028 DOI: 10.3109/10641963.2010.549276]

41 **Chen J**, Argemi J, Odena G, Xu MJ, Cai Y, Massey V, Parrish A, Vadigepalli R, Altamirano J, Cabezas J, Gines P, Caballeria J, Snider N, Sancho-Bru P, Akira S, Rusyn I, Gao B, Bataller R. Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. *Sci Rep* 2020; **10**: 15558 [PMID: 32968110 DOI: 10.1038/s41598-020-72172-7]

42 **Kameshima S**, Sakamoto Y, Okada M, Yamawaki H. Vaspin prevents elevation of blood pressure through inhibition of peripheral vascular remodelling in spontaneously hypertensive rats. *Acta Physiol (Oxf)* 2016; **217**: 120-129 [PMID: 26640237 DOI: 10.1111/apha.12636]

43 **Fathey H,** Wahid EA, Ahmad M, Fouad NT. Visceral Adipose Tissue-Derived Serine Protease Inhibitor (VASPIN) as A Prognostic Marker in Systemic Hypertension. *Egypt J Hosp Med* 2022; **86**: 877-881 [DOI: 10.21608/ejhm.2022.218044]

44 **Korolczuk A**, Bełtowski J. Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension. *Curr Pharm Des* 2017; **23**: 1533-1539 [PMID: 28120721 DOI: 10.2174/1381612823666170124114524]

45 **Kaur J**, Mukheja S, Varma S, Kalra HS, Khosa BS, Vohra K. Serum progranulin/tumor necrosis factor-α ratio as independent predictor of systolic blood pressure in overweight hypertensive patients: a cross-sectional study. *Egypt Heart J* 2020; **72**: 25 [PMID: 32424472 DOI: 10.1186/s43044-020-00063-3]

46 **Kong M**, Gao Y, Guo X, Xie Y, Yu Y. Role of the CTRP family in tumor development and progression. *Oncol Lett* 2021; **22**: 723 [PMID: 34429763 DOI: 10.3892/ol.2021.12984]

47 **Han S**, Jeong AL, Lee S, Park JS, Buyanravjikh S, Kang W, Choi S, Park C, Han J, Son WC, Yoo KH, Cheong JH, Oh GT, Lee WY, Kim J, Suh SH, Lee SH, Lim JS, Lee MS, Yang Y. C1q/TNF-α-Related Protein 1 (CTRP1) Maintains Blood Pressure Under Dehydration Conditions. *Circ Res* 2018; **123**: e5-e19 [PMID: 30030219 DOI: 10.1161/CIRCRESAHA.118.312871]

48 **Su Z**, Tian S, Liang W. Circulating CTRP1 Levels Are Increased and Associated with the STOD in Essential Hypertension in Chinese Patients. *Cardiovasc Ther* 2019; **2019**: 4183781 [PMID: 31772610 DOI: 10.1155/2019/4183781]

49 **Seccia TM,** Skander G, Belloni AS, Lenzini L, Pessina AC, Rossi GP. Expression of the adipokine ctrp-1 in the human adrenal gland: A link between hyperaldosteronism and hypertension in overweight-obese patients?: PP. 18.171. *J Hypertens* 2010; **28:** e301 [DOI: 10.1097/01.hjh.0000379097.00060.d9]

50 **Osaki A**, Shimizu H. Peripheral administration of nesfatin-1 increases blood pressure in mice. *Hypertens Res* 2014; **37**: 185-186 [PMID: 24048489 DOI: 10.1038/hr.2013.122]

51 **Zhao Y**, Ma X, Wang Q, Zhou Y, Zhang Y, Wu L, Ji H, Qin G, Lu J, Bi Y, Ning G. Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population. *Clin Exp Hypertens* 2015; **37**: 51-56 [PMID: 24678977 DOI: 10.3109/10641963.2014.897722]

52 **Güneş H**, Alkan Baylan F, Güneş H, Temiz F. Can Nesfatin-1 Predict Hypertension in Obese Children? *J Clin Res Pediatr Endocrinol* 2020; **12**: 29-36 [PMID: 31339256 DOI: 10.4274/jcrpe.galenos.2019.2019.0072]

53 **Lu QB**, Wang HP, Tang ZH, Cheng H, Du Q, Wang YB, Feng WB, Li KX, Cai WW, Qiu LY, Sun HJ. Nesfatin-1 functions as a switch for phenotype transformation and proliferation of VSMCs in hypertensive vascular remodeling. *Biochim Biophys Acta Mol Basis Dis* 2018; **1864**: 2154-2168 [PMID: 29627363 DOI: 10.1016/j.bbadis.2018.04.002]

**Footnotes**

**Conflict-of-interest statement:** All the authors declared no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 26, 2022

**First decision:** January 31, 2023

**Article in press:** March 6, 2023

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** Pakistan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Pahlavani HA, Iran **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Overall representation of levels of adipokines contributing role in the pathogenesis of hypertension.** Source: Designed by the authors with the help of articles, signs showed further information, *e.g.*, ↓-decreased levels, ↑ - increased levels.

**Table 1 Summary of studies which reported the major adipokine's role in hypertension patients**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Adipokines** | **The main finding in the pathogenesis of hypertension**  |
| David *et al*[5], 2020 | Chemerin | The long-term remodeling of blood vessels in hypertension was the proliferative effect which might be influenced due to the chemerin |
| Gu *et al*[6], 2014 | Chemerin | Chemerin is strongly associated with markers of inflammation and components of the metabolic syndrome in hypertensive subjects and was independently associated with hypertension after adjustment for age, gender and metabolic risk factors |
| Gu *et al*[7], 2015 | Chemerin | Chemerin levels were independently associated with the index of arterial function and early atherosclerosis in essential hypertension |
| Wójcik *et al*[8], 2020 | Chemerin | Elevated chemerin levels may be associated with increased systolic blood pressure in obese children |
| Yamamoto *et al*[9], 2021 | Chemerin (CMKLR1) | For the first time revealed that the increased protein expression of CMKLR1 in the paraventricular nucleus was at least partly responsible for systemic hypertension in spontaneously hypertensive rats SHR |
| Ferland *et al*[10], 2019 | Chemerin | Chemerin, not derived from the liver but potentially from adipose tissue, is an important driver of hypertension associated with high fat |
| Gunes *et al*[11], 2012 | Visfatin | The mean visfatin level was significantly higher in hypertensive patients |
| Wang *et al*[12], 2010 | Visfatin | Serum visfatin levels in Lyon hypertensive rats were elevated and associated with lipid metabolic abnormalities |
| Liakos *et al*[13], 2015 | Visfatin, apelin | The lower apelin and higher visfatin plasma levels in high normal BP subjects compared to normal or optimal BP individuals could partially explain the higher CV risk of the high normal BP group |
| Yu *et al*[14], 2019 | Visfatin | Association of hypertension and cerebrovascular accident with higher plasma visfatin levels |
| Kocelak *et al*[15], 2014 | Visfatin/NAMPT | The presence of hypertension was not associated with the plasma levels of visfatin/NAMPT in elderly subjects |
| Hsu *et al*[16], 2016 | Visfatin | Reported the association with subsequent renal function with increased circulating visfatin in nondiabetic hypertensive patients |
| Parimelazhagan *et al*[17], 2021 | Visfatin | Found a positive correlation between visfatin and diastolic blood pressure as well as high-density lipoproteins |
| Rotkegel *et al*[18], 2013 | Visfatin | Increased plasma visfatin concentration may play a significant role in the pathogenesis of hypertension in patients with visceral obesity |
| Kraus *et al*[20], 2015 | RBP4 | Elevated levels RBP4 contribute to insulin resistance and were correlated with increased prevalence of hypertension and myocardial infarction |
| Li *et al*[21], 2019 | RBP4 | RBP4 levels were closely correlated with blood pressure levels and might be involved in the regulation of left ventricular diastolic function in patients with essential hypertension |
| Deng *et al*[27], 2014 | RBP4 | RBP4 levels were increased in naive hypertensive patients; however, no differences were observed in obese or non-obese hypertensive subjects |
| Solini *et al*[22], 2009 | RBP4 | Retinol-binding protein-4 levels were increased in naïve hypertensive women and correlated with the degree of carotid intima-media thickness suggesting the participation of this adipocytokine in the modulation of the atherosclerotic process exert by the adipose tissue as an endocrine organ |
| Zhang *et al*[28], 2017 | RBP4 | Serum RBP4 level was significantly higher and closely associated with BP in prehypertensive Chinese |
| Stuck *et al*[29], 2010 | RBP4 | Lowering serum RBP4 may be a novel therapeutic tool for hypertension with additive effects to current standard treatments that focus on the inhibition of the angiotensin system |
| Peng *et al*[30], 2017 | PAI-1 | Plasma PAI-1 may contribute to the development of hypertension through pathways beyond traditional risk factors  |
| Srikumar *et al*[31], 2002 | PAI-1 | PAI-1 levels were correlated with plasma renin activity, aldosterone, and insulin resistance in hypertensive subjects |
| Kaikita *et al*[32], 2001 | PAI-1 | Direct inhibition of vascular PAI-1 activity may provide a new therapeutic strategy for the prevention of arteriosclerotic cardiovascular disease |
| Ritter *et al*[34], 2017 | MCP-1 | The study suggests a possible downregulation in MCP-1 levels in hypertensive individuals with LVH, regardless of hypertension strata  |
| Wang *et al*[35], 2015 | MCP-1 | Indicate that deletion of transient receptor potential vanilloid type 1 TRPV1 aggravated the renal injury in salt-sensitive hypertension via enhancing MCP-1/CCR2 signaling-dependent inflammatory responses  |
| Çelik *et al*[36], 2021 | Omentin-1 | Authors demonstrated that serum omentin-1 levels decreased in patients with hypertension as compared with normotensive controls, which could be attributed to a combined outcome of endothelial dysfunction, inflammation as well as renal injury in the setting of hypertension |
| Dong *et al*[37], 2021 | Omentin-1 | The down-regulation of omentin-1 induces endothelial dysfunction and hypertension in obesity. Tetrahydroxystilbene [glycoside](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/glycoside) treatment (at least partially) increases omentin-1 via promoting the binding of peroxisome proliferator-activated receptor-γ (PPAR-γ) and intelectin-1 (Itln-1) promoter in adipose tissues, subsequently exerts protective effects on endothelial function via activating Akt/eNOS/NO signaling and attenuating oxidative/nitrative stress |
| Cetin *et al*[38], 2022 | Omentin-1 | The study suggests that circulating omentin-1 levels were inversely related to the presence of MetS and may be a reliable marker to predict the development of MetS in patients with hypertension |
| Song *et al*[39], 2014 | Lipocalin-2 | Administration of lipocalin-2 causes abnormal vasodilator responses in mice on a high-fat diet. Polyamination facilitates the clearance of lipocalin-2, whereas the accumulation of deamidated lipocalin-2 in arteries causes vascular inflammation, endothelial dysfunction, and hypertension |
| Ong *et al*[40], 2011 | LCN2 | The author's findings suggest, for the first time, that genetic variants in LCN2 may affect BP |
| Chen *et al*[41], 2020 | LCN2 | The contributing role of LCN2 in liver fibrosis as well as portal hypertension in alcoholic hepatitis and might represent a new therapeutic target |
| Kameshima *et al*[42], 2015 | Vaspin | A study for the first time demonstrates that vaspin prevents the increase of SBP in SHR by inhibiting peripheral vascular hypertrophy, possibly via antioxidative and anti-inflammatory mechanisms |
| Fathey *et al*[43], 2022 | Vaspin | Plasma vaspin may be used as an independent predictive biomarker for the early detection of macrovascular and/or microvascular hypertensive complications |
| Kaur *et al*[45], 2020 | PGRN | Findings of reduced PGRN/TNF ratio, and it was an independent predictor of SBP, ascertain the key role of imbalance in the pro-and anti-inflammatory environment in hypertension |
| Han *et al*[47], 2018 | CTRP1 | CTRP1 contributes to the regulation of BP homeostasis by preventing dehydration-induced hypotension |
| Su *et al*[48], 2019 | CTRP1 | CTRP1 levels were increased and associated with STOD (heart and kidney) in essential hypertension, which can be regarded as a novel biomarker in the prediction of prognosis for patients with essential hypertension |
| Seccia *et al*[49], 2010 | CTRP1 | CTRP-1 was expressed in myelolipomas together with adenomas that produce aldosterone raising the possibility that CTRP-1 may cause an excess of aldosterone and the growth of ZG cells |
| Osaki *et al*[50], 2014 | Nesfatin-1 | Nesfatin-1 may probably be a new key molecule involved in hypertension and can be used as an anti-obesity and anti-T2DM medication |
| Zhao *et al*[51], 2015 | Nesfatin-1 | Fasting plasma nesfatin-1 levels were significantly higher in hypertension patients than in the control group, especially in overweight/obese hypertension patients |
| Güneş *et al*[52], 2020 | Nesfatin-1 | Nesfatin-1 levels were higher and an independent predictor of hypertension in obese subjects |
| Lu *et al*[53], 2018 | Nesfatin-1 | Nesfatin-1 is a key modulator in hypertension and vascular remodeling by facilitating vascular smooth muscle cells (VSMC) phenotypic switching and proliferation |

CV: Cardiovascular; NAMPT: Nicotinamide phosphoribosyl transferase; RBP4: Retinol-binding protein 4; PAI-1: Plasminogen activator inhibitor-1; MCP-1: Monocyte chemotactic protein-1; LVH: Left ventricular hypertrophy; CCR2: C-C chemokine receptor type 2; BP: Blood pressure; LCN2: Lipocalin-2; SBP: Systolic blood pressure; SHR: Spontaneously hypertensive rats; PGRN: Progranulin; TNF: Tumor necrosis factor; CTRP1: C1q/TNF-α–related protein 1; STOD: Subclinical target organ damage; ZG: Zona glomerulosa.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**